Blockbuster Enhertu may get tumor agnostic label, targeting any HER2-expressing cancer: GlobalData Read more
Biliary tract cancer drug Durvalumab approval key opportunity for AstraZeneca in India: GlobalData Read more
AstraZeneca’s Durvalumab gets CDSCO nod to treat locally advanced or metastatic biliary tract cancer Read more
USFDA accepts AstraZeneca’s BLA for nirsevimab to prevent RSV lower respiratory tract disease Read more